George Steuart Health

George Steuart Health (GS Health) is one of Sri Lanka's foremost distributors of pharmaceutical and non-pharmaceutical products. During three decades of operations, the company has built a formidable network of agency partnerships with over 70 global healthcare giants in 15 countries, including world leading manufacturers such as B Braun (Germany), Abbott (United States), Celltrion (South Korea), Unique Pharmaceuticals (India), Biopharm (Thailand), United Laboratories (Philippines), Nabiqasim (Pakistan) and Centaur (India) etc.

The George Steuart Health's advantage has been its deep knowledge of the healthcare space in Sri Lanka and a commitment to understand and cater to the needs of the medical community, thereby sourcing products that match medical requirements and enable better outcomes. It has established an extensive trade presence in Sri Lanka spanning over 5,100 outlets, including pharmacies, stocking doctors and modern trade. The company employs a well-trained, knowledgeable field force of over 400 representatives nationwide and is well supported by a distribution network that is renowned for its modern infrastructure and stateof- the-art warehousing.

In an intensely competitive market, George Steuart Health has consistently been ranked among the top four players in the pharmaceutical segment, which represents the largest share of the company's revenue. It markets over 600 pharmaceutical products in recognised formulations across all therapeutic segments.

George Steuart Health engages in over 15 other nonpharmaceutical product categories such as diagnostics, surgical devices, medical devices, neutraceuticals, cosmetics, veterinary medicines, sports fitness and rehabilitation, and optometry. Its consumer division markets a suite of health and wellness products, representing international brands.

George Steuart Health was instrumental in revolutionising the diagnostics landscape in Sri Lanka with the introduction of rapid diagnostics in 2009, which has led to the improvement of detection and treatment of diseases such as Dengue Fever, Influenza, AIDS, Covid-19, and many other infectious diseases.

Currently 90% of the total of sales of the George Steuart Health is generated from the private sector while the rest is accounted by the state sector.

The company has commenced its entry into the pharmaceutical manufacturing space. Under its subsidiary 'Seregen (Pvt) Ltd', the company will manufacture Generic, Cardiac and Diabetic pharmaceuticals at its plant located in Horana. Furthermore, George Steuart Health will expand its manufacturing into diagnostics, bioceuticals and dermotological products.